title: Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness.
abstract: The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score was greater than 7. Statin users comprised 30.9% of those studied. The PCa detection rate was 31.2% of men on statins and 37% of non-statin users (p<0.006). The PCa detection rate was 26.3% in men with NSC and 40.6% in those with HSC (p<0.001). In the subset of NSC men, the PCa rate was 26.5% for statin users and 26.2% for non-users (p=0.939), while in men with HSC, the PCa rate was 36.4% for statin users and 42.0% for non-statin users (p=0.063). The HGPCa rate was 41.8% for statin users and 32.5% for non-users (p=0.012). NSC men had a 53.8% rate of HGPCa, while the rate was only 27.6% in HSC men (p<0.001). NSC men on statins had an HGPCa rate of 70.2%, while non-statin users had a rate of 41.2% (p<0.001). The HGPCa rate for HSC men on statins was 18.8%, while the rate was 30.0% (p=0.011) for non-users. Logistic regression analysis suggested that serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1.87 (95% CI 1.56-2.24) and HGPCa risk, OR 0.31 (95% CI 0.23-0.44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol.
authors.affiliation: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. jmorote@vhebron.net.
authors.forename: Juan
authors.initials: J
authors.lastname: Morote
authors.affiliation: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. acelma@vhebron.net.
authors.forename: Anna
authors.initials: A
authors.lastname: Celma
authors.affiliation: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. jplanas@vhebron.net.
authors.forename: Jacques
authors.initials: J
authors.lastname: Planas
authors.affiliation: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. jplanas@vhebron.net.
authors.forename: José
authors.initials: J
authors.lastname: Placer
authors.affiliation: Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. itorres@vhebron.net.
authors.forename: Inés
authors.initials: I
authors.lastname: de Torres
authors.affiliation: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. mireia.olivan@vhir.org.
authors.forename: Mireia
authors.initials: M
authors.lastname: Olivan
authors.affiliation: Department of Medical Oncology, Vall d'Hebron University and Hospital Autonomous University of Barcelona, Barcelona 08035, Spain. jocarles@vhebron.net.
authors.forename: Juan
authors.initials: J
authors.lastname: Carles
authors.affiliation: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. jaume.reventos@vhir.org.
authors.forename: Jaume
authors.initials: J
authors.lastname: Reventós
authors.affiliation: Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain. andreas.doll@vhir.org.
authors.forename: Andreas
authors.initials: A
authors.lastname: Doll
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016017:Odds Ratio; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol
references.citation: Ann Oncol. 2006 Jun;17(6):1014-7
references.pmid: 16611646
references.citation: Int J Cancer. 2008 Aug 15;123(4):899-904
references.pmid: 18491405
references.citation: Eur J Cancer. 2010 Nov;46(17):3040-52
references.pmid: 21047585
references.citation: Br Med J (Clin Res Ed). 1982 Jan 16;284(6310):152-4
references.pmid: 6799076
references.citation: Nat Rev Cancer. 2005 Dec;5(12):930-42
references.pmid: 16341084
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13
references.pmid: 19887582
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32
references.pmid: 18006910
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2653-9
references.pmid: 20421534
references.citation: Pharmacotherapy. 2010 Feb;30(2):177-94
references.pmid: 20099992
references.citation: PLoS One. 2012;7(10):e46691
references.pmid: 23049713
references.citation: Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36
references.pmid: 17944002
references.citation: Lancet. 2011 Feb 12;377(9765):529-32
references.pmid: 21295845
references.citation: J Clin Epidemiol. 1988;41(6):519-30
references.pmid: 3290396
references.citation: J Chronic Dis. 1986;39(11):861-70
references.pmid: 3793838
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7
references.pmid: 17971518
references.citation: J Natl Cancer Inst. 2008 Jan 16;100(2):134-9
references.pmid: 18182618
references.citation: J Urol. 2005 Oct;174(4 Pt 1):1256-60; discussion 1260-1; author reply 1261
references.pmid: 16145388
references.citation: Cancer Causes Control. 2010 Jan;21(1):61-8
references.pmid: 19806465
references.citation: J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8
references.pmid: 18957682
references.citation: Am J Cancer Res. 2011;1(4):542-61
references.pmid: 21984972
references.citation: Cancer Causes Control. 2011 Nov;22(11):1545-52
references.pmid: 21915616
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Int J Cancer. 2010 Oct 1;127(7):1650-9
references.pmid: 20073066
references.citation: Cancer Causes Control. 2008 Sep;19(7):767-74
references.pmid: 18322813
references.citation: Prostate Cancer Prostatic Dis. 2011 Dec;14(4):340-5
references.pmid: 21727905
references.citation: Am J Epidemiol. 1989 Mar;129(3):511-7
references.pmid: 2916544
references.citation: Int J Cancer. 2008 Oct 1;123(7):1693-8
references.pmid: 18646186
references.citation: BMC Cancer. 2012 Jan 19;12:25
references.pmid: 22260413
references.citation: Cancer Causes Control. 2011 Feb;22(2):311-8
references.pmid: 21116843